GlassScriptPhysician profile
Grace Brenner
NPI 1609641570
$1,519.82
in general payments reported to CMS, 2019-2025
21 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,246 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.93 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $264.09 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.56 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $123.49 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $86.62 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $67.84 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $59.22 | 2024 | |
| Pfizer INC. | $49.93 | 2024 | |
| Glaxosmithkline, LLC. | $47.00 | 2024 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $40.81 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.49 | 2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $34.47 | 2024 | Voquezna |
| Exact Sciences Corporation | $29.81 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $29.14 | 2024 | Zepbound, Jardiance, Mounjaro |
| Ascendis Pharma Endocrinology INC | $28.00 | 2025 | Yorvipath |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.17 | 2025 | Auvelity |
| Alexion Pharmaceuticals, INC. | $19.80 | 2024 | Strensiq |
| Amgen INC. | $19.65 | 2024 | Krystexxa |
| Tolmar, INC. | $18.99 | 2024 | |
| Amneal Pharmaceuticals LLC | $18.11 | 2024 | Unithroid |
| Antares Pharma, INC. | $15.70 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.